- Nektar Therapeutics (NASDAQ:NKTR) initiated with Buy rating and $35 (16% upside) price target by Canaccord Genuity.
- AnaptysBio (NASDAQ:ANAB) initiated with Buy rating and $101 (54% upside) price target by Jefferies.
- Acorda Therapeutics (NASDAQ:ACOR) initiated with Neutral rating and $27 (6% downside risk) by Oppenheimer.
- GTx (NASDAQ:GTXI) initiated with Buy rating and $16 (113% upside) price target by Stifel.
- Idera Pharmaceuticals (NASDAQ:IDRA) initiated with Buy rating and $4 (126% upside) price target by H.C. Wainwright.
- Biogen (NASDAQ:BIIB) initiated with Outperform rating and $350 (12% upside) price target by Oppenheimer.
- Alnylam Pharmaceuticals (NASDAQ:ALNY) upgraded to Overweight by JPMorgan (NYSE:JPM).
- Amphastar Pharmaceuticals (NASDAQ:AMPH) downgraded to Market Perform by Raymond James.
- Amedisys (NASDAQ:AMED) downgraded to Hold by Benchmark.
- Egalet (NASDAQ:EGLT) downgraded to Hold by Gabelli.
- QuintilesIMS (NYSE:Q) downgraded to Neutral by MIzuho.
- Selecta Biosciences (NASDAQ:SELB) downgraded to Neutral by UBS.
- Source: Bloomberg
- Now read: Acorda Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides
Original article